Advertisement

Pityriasis Rosea

  • Danya Reich
  • Corinna Eleni Psomadakis
  • Bobby Buka
Chapter

Abstract

Pityriasis rosea is an acute viral rash associated with reactivation of latent human herpersvirus types 6 and 7. The rash is characterized by the appearance of an initial lesion, called a herald patch, followed by additional smaller lesions of a similar appearance, primarily on the trunk. Pityriasis rosea lesions are oval, salmon-colored patches and plaques with central scale. The onset of the rash is sometimes preceded by symptoms of an upper respiratory tract infection. Pityriasis rosea is self-limiting, and does not require treatment unless patients require symptomatic relief. Oral antivirals initiated within the first week of symptoms are associated with speedier clearance of the rash. For most people there are no complications associated with the condition; however, women in their first 20 weeks of pregnancy who get pityriasis rosea experience higher rates of miscarriage, premature delivery, and perinatal problems.

Keywords

Pityriasis rosea Eruption Exanthem Infection Human herpesvirus Herpes virus Herpes HHV 6 HHV 7 Acute Herald patch Pregnancy Spontaneous abortion Miscarriage Pruritus Antihistamine Acyclovir 

References

  1. 1.
    Drago F, Broccolo F, Ciccarese G, Rebora A, Parodi A. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology. 2015;230(1):23–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Broccolo F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, Gelmetti C, Lusso P, Rebora AE, Malnati MS. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol. 2005;124(6):1234–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Blauvelt A. Chapter 42. Pityriasis rosea. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. Available from: http://accessmedicine.mhmedical.com.ezproxy.cul.columbia.edu/content.aspx?bookid=392&Sectionid=41138739. Accessed 27 Feb 2015.Google Scholar
  4. 4.
    Drago F, Broccolo F, Zaccaria E, Malnati M, Cocuzza C, Lusso P, Rebora A. Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol. 2008;58(5 Suppl 1):S78–83.CrossRefPubMedGoogle Scholar
  5. 5.
    Ganguly S. A randomized, double-blind, placebo-controlled study of efficacy of oral acyclovir in the treatment of pityriasis rosea. J Clin Diagn Res. 2014;8(5):YC01–4.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol. 2006;54(1):82–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Drago F, Ciccarese G, Rebora A, Parodi A. Relapsing pityriasis rosea. Dermatology. 2014;229(4):316–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • Danya Reich
    • 1
  • Corinna Eleni Psomadakis
    • 2
  • Bobby Buka
    • 3
  1. 1.Department of Family MedicineMount Sinai School of Medicine Attending Mount Sinai Doctors/Beth Israel Medical Group-WilliamsburgBrooklynUSA
  2. 2.School of Medicine Imperial College LondonLondonUK
  3. 3.Department of DermatologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations